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ABSTRACT 
Malignant hyperthermia/hyperpyrexia (MH) is a serious human skeletal 
muscle disorder that manifests itself during general anaesthesia. 
Currently, the most reliable method of diagnosing this disease is the in· 
- vitro contracture test (IVCT). This procedure is both highly invasive for the 
patient and expensive to perform. The skinned muscle fibre technique is 
less invasive, and could possibly be used as an alternative diagnostic test 
for MH. 
In this study, skeletal muscle samples were obtained from 8 adults (age 
23-54 years) undergoing elective surgery at Royal Perth Hospital. Six 
patients were diagnosed as normal (controls) and two equivocal for MH 
(MHE). Using the skinned muscle fibre technique (with exogenous Ca2+ 
. and sr2+), individual muscle fibre segments (10 from each biopsy) were 
tested for differences in their contractile and regulatory proteins, and the 
generated force per cross-sectional area (F/CSA). The results indicated 
that the contractile and regulatory proteins of the · MH E fibres displayed 
altered functionality in comparison to the control fibres. The Type I MHE 
fibres displayed greater sensitivity to Sr2+ (82%), whereas the Mixed MHE 
fibres displayed greater sensitivity to Ca2+ (90%). However, the F/CSA 
generated by the MHE fibres were overall less .than that of the control 
- . 
fibres {43%), denoting statistical insignificance. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background to the study 
Malignant Hyperthermia is a pharmacogenetic disorder affecting human 
skeletal muscle under the influence of the inhalant general anaesthetic 
halothane, and the depolarising muscle relaxant suxamethonium. The 
disease was first recognised in Australia in 1960 by Denborough and 
Lovell, who discovered a family in which ten members died spontaneously 
'Nhilst under general anaesthesia (Joffe, Savage & Silove, 1992; 
Mccomas, 1996). 
Studies by Walter (1981) and Joffe et al. (1992) determined that there was 
a defect in the ryanodine receptors (calcium release channel) of the 
sarcoplasmic reticulum (SR) within skeletal muscle. On exposure to 
halothane or suxamethonium, these receptors release excess calcium into 
the muscle fibres, resulting in skeletal muscle contracture. This prolonged 
contraction of skeletal muscle results in hyperthermia, tachycardia and 
cardiac arrest (Joffe et al., 1992). 
Currently the most reliable method of diagnosing malignant hyperthermia 
(MH) .is the in-vitro contracture test (IVCT): it is highly invasive for the 
-·- ,, .. -··-·- _· ~· --···-·- --·· --- -----· 
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patient and relatively expensive. The IVCT involves the removal of muscle 
from the patient's thigh, and exposing it to controlled levels of halothane 
and caffeine while continuously monitoring tension (Britt, 1979; Joffe et al., 
1992; Serfas, Bose, Patel, Wrogemann, Phillips, Maclennan & 
Greenburg, 1996). Research is currently underway to find a less invasive 
technique than the IVCT of diagnosing the disease without compromising 
accuracy (Takagi, Sunohara, Ishihara, Nonaka & Sugita, 1983). 
The skinned muscle fibre technique involves the chemical (or mechanical) 
removal of the cell membrane of the muscle fibre. The sarcoplasmic 
reticulum (SR) is also disrupted ensuring that all the internal calcium is 
removed. This therefore allows control over the environment within the 
muscle cell (Britt, Frodis, Scott, Clements & Endrenyi, 1982; Fink, 
Stephenson & Williams, 1990). The technique (which was used in this 
study) has been applied to the testing of muscle biopsies, 1M1ere caffeine 
is added to the muscle tissue. This is because caffeine has been found to 
induce extreme skeletal muscle contraction (Takagi et al., 1983). This will 
be discussed in detail later. However, in this skinned muscle fibre 
technique, calcium and strontium ions are normally used to activate the 
muscle fibre. The technique has been applied to many questions in muscle 
physiology, notably Duchenne Muscular Dystrophy (Fink et al., 1990). 
. ' 
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1.2 Significance of the Study 
Current diagnostic techniques for MH are highly invasive, requiring a large 
skeletal muscle biopsy to be taken from the patient's thigh in the operating 
theatre, v.tiich is both painful to the patient and expensive to the 
. community (Allen, Larach & Kunselman, 1998). Skinned fibre studies 
require a much smaller biopsy (even needle biopsies have proven reliable) 
and do not necessitate theatre time (Takagi et al., 1983). It is hoped that 
this study will validate the use of a modified skinned muscle fibre 
technique as a possible diagnostic test for MH. In addition, greater detail 
will be revealed about the pathophysiology of MH, such as the effects of 
calcium and strontium ions on the contractile apparatus. 
1.3 Purpose of the Study 
The purpose of this project is to examine the contractile responses/kinetics 
of MH muscle to exogenous calcium and strontium ion activation in 
comparison to that of normal human muscle. If significant differences are 
~ ! 
identified then this technique may be ab!a to be employed diagnostically 
with significant advantages to the patient and to hospital budgets. The 
results may also aid in the understanding of the contradile and regulatory . 
proteins of MH muscle and possibly determine why the MH muscle reacts 
differently to certain pharmacological agents than does normal muscle . 
.... 
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1.4 Research Questions 
• Are the functions of the contractile proteins, (myosin S1 subfragments) 
affected by MH? 
• Are the functions of the regulatory proteins, (tropomyosin and troponin) 
affected by MH? 
• Is the skinned muscle fibre method (employed in this study) a suitable 
candidate for testing for MH? 
1.5 Hypotheses 
• Individual MH muscle fibres display differing kinetics of contraction to 
exogenous calcium and strontium ion activation than individual muscle 
fibres in normal ( control) human muscle. 
• The force per cross-sectional area generated by MH muscle fibres is 
different to that of normal (control) muscle. 
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1.6 Definition of Terms/Abbreviations 
• Actin: a "thin" protein filament responsible for the contraction of skeletal 
and cardiac muscle 
• Ala: alanine, an amino acid 
• Arg: arginine, an amino acid 
" Contracture: permanent muscle contraction in the absence of nervous 
stimulation 
• Cys: cysteine, an amino acid 
• Cytoskeleton: the internal skeleton in the cytosol of a cell 
• Depolarise: to make a cell's resting membrane potential more positive 
(or less negative) as measured inside with respect to the outside 
• DHPR: dihydropyridine receptor, a protein molecule involved in the link 
between the sarcoplasmic reticulum and transverse tubules in the 
muscle 
• Dystrophin: a protein found in skeletal and cardiac muscle 
• Gly: glycine, an amino acid 
• Halothane: an inhalant anaesthetic widely used in general anaesthesia 
• His: histidine, an amino acid 
• Hyperthermialhyperpyrexia: an exceedingly high body temperature, 
defined as being over 41°C 
• IV: intravenous administration 
• IVCT: in-vitro contracture test - exposing muscle biopsies to caffeine 
and halothane to diagnose MH by monitoring the resultant contracture 
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• Kinetic: pertaining to or producing motion 
• Malignant: to become progressively worse and to result in death 
• Malignant Hyperthermia/Hyperpyrexia (MH): a serious skeletal muscle 
disorder arising during general anaesthesia that results in hyperthermia 
and death 
• MHE: Malignant Hyperthermia Equivocal - a patient who tests positive 
to either caffeine or halothane (borderline cases) but are clinically 
treated as MHS 
• MHN: Malignant Hyperthermia Normal - a patient who tests negative to 
caffeine and halothane to the IVCT 
• MHS: Malignant Hyperthermia Susceptible - a patient who tests 
positive to caffeine and halothane to the IVCT 
• Myofibril: a subdivision of a muscle cell consisting of a series of 
sarcomeres (contractile units) 
• Myosin: a "thick" protein filament responsible for the contraction of 
skeletal and cardiac muscle 
• Pharmacogenetic: a genetic abnormality that is triggered by the 
administration of a particutar drug or a combination of drugs 
• PSS: Porcine Stress Syndrome - the MH equivalent in certain breeds 
of pig 
• RCT: ryanodine contracture test - using high purity ryanodine (98%) on 
muscle biopsies to diagnose MH 
• Ryanodine: a nitrogenous substance (alkaloid) found in plants 
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• Ryanodine receptor: a receptor mainly found in skeletal and cardiac 
muscle (on the SR) that releases calcium into the contractile unit 
• RYR1: ryanodine receptor 1 gene - one of the possible genes located 
on chromosome 19 that has been linked to some MH sufferers 
• S1 subfragment: another name for the globular heads of the myosin 
filament necessary for the contradion of muscle 
• Sarcomere: the contractile unit of skeletal and cardiac muscle, 
consisting of sliding filaments of adin and myosin 
• Sarcoplasm: the cytoplasm (cytosol "fluid portion" and organelles) of a 
muscle cell - also called myoplasm 
• Sarcoplasmic Reticulum (SR): a membrane network similar to 
.· endoplasmic reticulum surrounding each myofibril that contains 
supplies of calcium ions for normal muscle contraction 
• Suxamethonium: a neuromuscular blocking agent causing muscle 
relaxation that is commonly used in abdominal surgery - also called 
succinylcholine chloride 
• Tropomyosin: a protein strand that covers the active site of an actin 
molecule during relaxation 
• Troponin: three globular. proteins arranged over the tropomyosin and 
actin molecule and contains the calcium receptor needed for 
contraction 
• Type I fibre (slow-twitch): red coloured skeletal muscle that primarily 
uses aerobic metabolism as an energy supply during contraction 
: 
~------·----
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• Type II fibre (fast-twitch): white coloured skeletal muscle that primarily 
uses anaerobic metabolism as an energy supply during contraction 
• Vastus media/is: one of the four heads of the quadriceps muscle 
located on the anteromedial aspect of the human femur 
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CHAPTER2 
LITERATURE REVIEW 
2.1 Introduction 
Malignant hyperthermia/hyperpyrexia (MH) is a pharmacogenetic disorder 
affecting human skeletal muscle fibres (Joffe et al., 1992). Inhalant general 
anaesthetics such as halothane and depolarising muscle relaxants such 
as suxamethonium, and their derivatives, are the agents that may trigger 
an MH attack in malignant hyperthermia susceptible (MHS) and malignant 
hyperthermia · equivocal (MHE) individuals (McCarthy, Tong & Maclennan, 
1998). Malignant hyperthermia is also present in certain breeds of swine 
(Pietran and Lane/race), where an attack can be induced by both stress 
and trigger agents. This is generally called Porcine Stress Syndrome 
(PSS) (Joffe et al., 1992). In humans, MH is one of the major causes of 
general anaesthetic related deaths, (approximately 4% of cases) (Lane, 
1996). However, with the intravenous (IV) administration of the muscle 
relaxant dantrolene, the death rate is significantly reduced (Healy, Quane, 
Keating, Lehane, Heffron & McCarthy, 1996). 
L _____________________ ----------------------
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2.2 History 
Malignant hyperthermia was first recognised in Australia in 1960 by 
Denborough and Lovell, who discovered a family of which ten members 
died after been given a triggering agent during general anaesthesia (Joffe 
et al., 1992; Mccomas, 1996). The disease was subsequently 
incorporated into the International Classification of Diseases in 1983 
(Merz, 1986). 
In 1971, the in-vitro contracture test (IVCn using caffeine and halothane 
was described at the First International Symposium on MH (Toronto, 
Canada) in humans, and in 1975 the effects of dantrolene (a drug known 
to reverse the symptoms), in pigs at the Second International Symposium 
on MH (Katz, 1992). Dantrolene was approved by the US Food and Drug 
Administration (FDA) in 1979 for use in humans and by 1983 the IVCT 
was standardised to utilise caffeine and halothane on a biopsy removed 
from a quadricep muscle. The patient was then diagnosed as either 
malignant hyperthermia normal (see Section 2.10 p. 23) (MHN), MHS, or 
MHE (European Malignant Hyperpyrexia Group, 1984; Katz, 1992). 
11 
2.3 Incidence 
MH occurs in 1 in 12,000 to 15,000 paediatric general surgical cases, and 
1 in 40,000 to 100,000 adult general surgical cases (Joffe et al., 1992; 
Sorrentino & Volpe, 1993; Pennington & Joeris, 1996; Dunn, 1997; Lake & 
Maclennan, 1998). The most frequent age group for this disease is from 3 
years of age through to 30 years of age, with males more commonly 
affected (Lane, 1996). Porcine stress syndrome (PSS) occurs in up to 90% 
of stress susceptible pigs (Joffe et al., 1992). Sporadic cases of MH have 
occurred in thoroughbred racehorses and in greyhounds, cats, cattle and 
__ even giraffes (Lane, 1996). 
2.4 Trigger Agents 
In humans, MH is precipitated by exposure to inhalant anaesthetics, such 
as halothane, and depolarising muscle relaxants, such as suxamethonium 
(McCarthy et al., 1998). 
Halothane (Fluothane, ICI Pty Ltd) is a_ fluorinated hydrocarbon _ that has 
widespread use in general anaesthesia, due to -the fad that it causes little 
irritation to the respiratory tract, and -usually does not initiate the cough 
reflex. Halothane is usually combined with another inhalant anaesthetic, 
nitrous oxide to maintain anaesthes,ia following induction (Galbraith, 
L 
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B1.1llock & Manias, 1994). Halothane is the most common and stronges-t 
trigger in MHS individuals (Lane, 1996). The other fluorinated 
hydrocarbons related to halothane, which also trigger MH reactions are 
isofl urane, sevoflurane, enflurane, desflurane, and methoxyflurane 
(Galbraith et al., 1994; Malignant Hyperthermia Association of the United 
States, 1997; MIMS, 1997). 
Suxamethonium (Scoline, David Bull Pty Ltd) is a depolarising muscle 
relaxant commonly used in abdominal surgery, as most general 
anaesthetics do not relax the abdominal muscles sufficiently (Galbraith et 
al., 1994; MIMS, 1997; McCarthy et al., 1998). This drug is structurally 
similar to the neurotransmitter acetylcholine. It acts as an acetylcholine 
agonist on the nicotinic receptors of the motor end plate, by binding to the 
motor end plate, inducing prolonged depolarisation and preventing 
. ' 
transmission of any neural impulses. This results in total muscle paralysis 
(Galbraith et al., 1994). Normally after IV administration, the skeletal 
· _ muscles go into total spasm, then after a second or so the body should go 
· totally flaccid. Hawever, . in MH individuals, the skeletal muscles remain 
rigid (Galbraith et al., 1994), which strongly indicates that the 
··' 
pathophysiology does· not involve the continual. depolarisation of the 
muscle fibres. 
In both . humans and pigs, halothane and · suxamethonium (and their 
derivatives) cause the release·of calcium into the sarcoplasm, resulting in 
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increased metabolic activity and contracture of the skeletal muscles 
(Galbraith et al., 1994). The defect lies in the ryanodine receptor (see 
Section 2.6 p. 16) of the sarcoplasmic ret_iculum (SR) surrounding 
individual myofibrils. 
2.5 Skeletal Muscle Contractile Apparatus 
Skeletal muscle is composed of many contractile units (sarcomeres) that 
are necessary for muscle function. Sarcomeres contain two major 
contractile proteins called actin (thin filaments) and myosin (thick 
filaments). Other proteins involved are found associated with the Z line 
(intermediate fi lament), the M line. The Z line is made up of the protein 
connectin and it interconnects the actin filaments between each adjacent 
sarcomere. The M line stabilises the myosin filaments in the centre of the 
sarcomere. Anot~er protein titin, stabilises this structure by linking the 
myosin filaments to the Z line (Figure 2.1) (Mccomas, 
1996; Martini, 1998). 
I band A band 
-·~-----~ 
"yosin 
tin 
Z line 
Figure 2.1. Two dimensional structure of a sarcomere 
(Source: Martini, 1998) 
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Actin filaments measure approximately 6-Bnm wide and 1 µm long. The 
filament consists of troponin (3 subunits), tropomyosin and between 300-
400 actin molecules (Figure 2.2). The three troponin subunits consists of: 
troponin T that attaches to the tropomyosin; troponin / that binds to the 
actin molecule, and troponin C that binds to calcium (Mccomas, 1996). 
Myosin filaments measure approximately 12nm wide and between 1.5-
1.6µm long. This filament comprises of a single "tail" and two globular 
cross-bridge "heads" (also called the S1 subfragments) (Figure 2.3) 
(Martini, 1998). 
Troponin 
Figure 2.2. Structure of the actin filament 
(Source: Martini, 1998) 
Figure 2.3. Structure of the myosin filament 
(Source: Martini, 1998) 
Actin 
molecule 
Head 
In a resting state, a sarcomere (defined as the functional unit of 
contraction between two Z lines) measures approximately 2.6µm long, and 
when viewed using optical microscopy, comprise of light and dark "bands" 
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consisting of the above filaments. The A band contains the zone of overlap 
between the actin and myosin1 the I band contains only actin, and the H 
band contains only myosin and the M line. The naming of the A and I 
bands were derived from the appearance viewed under polarised light. 
Anisotropic (A band), light absorbing, and isotropic (I band), light 
transmitting, were the tenns given (Martini, 1998). 
The rationale of skeletal muscle contraction is still referred to as the 
Sliding Filament Theory, devised by Huxley in the ear1y 1950s (Mccomas, 
1996). During contraction, the myosin cross-bridge heads attach 
themselves to specific binding sites on the actin molecules (active site), 
causing the heads to pivot backwards, sliding the actin filaments towards 
the M line, and then releasing. This is called "cross-bridge cyding". For 
contraction to be initiated, calcium ions have to be released from the SR 
through the ryanodine receptors, increasing th\3 intracellular concentration 
from 10.aM to around 10~. Calcium binds to the troponin (troponin C) 
which causes the troponin and tropomyosin to reflect away from the actin 
binding site and allow the myosin heads to attach, permitting cross-bridge 
cycling (Mccomas, 1996; Martini, 1998). 
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2.6 Skeletal Muscle Fibre Types 
In general, there are three distinct categories of muscle fibre types that 
have varying properties. There are slow fibres {Type I), fast fibres (Type 
II B) and intermediate fibres (Type IIA). Slow or red fibres have a slow 
contraction speed (50-100msec) and a relatively small aoss sectional 
diameter (10-50µm) (Martini, 1998). Its colouring is due to a high 
myoglobin (muscle haemoglobin) content that has plentiful oxygen 
reserves (Peachey, Adrian & Geiger, 1983). These fibres are primarily 
used for prolonged contractions such as postural maintenance, therefore 
they have many mitochondria that use aerobic metabolism (Peachey et al., 
1983). Fast or white fibres have a fast contraction speed of 10msec or less 
and have a large cross sectional diameter (50-100µrn). These fibres have 
a low myoglobin content and very few mitochondria, therefore they rely on 
large glycogen reserves (anaerobic metabolism) for energy (Peachey et 
al., 1983; Martini, 1998). These fibres produce powerful contractions for 
activities such as sprinting and lifting, but fatigue rapidly (Martini, 1998). 
Intermediate fibres are similar to fast fibres in appearance and 
metabolism, however they do not fatigue as easily (Peachey et al., 1983; 
Martini, 1998). 
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2. 7 Ryanodlne Receptor 
The ryanodine receptor is the principal channel through '-Nhich calcium is 
released from the sarcoplasmic reticulum (SR) into the sarcoplasm. The 
naming of the receptor comes from the plant alkaloid ryanodine, as it was 
found experimentally that this protein has a high affinity to these receptors 
(Joffe et al., 1992). 
The receptor is divided into four domains or radial channels that are 
connected to a 2nm central channel, and has a four leaf clover 
appearance (see Figure 2.4) (Joffe et al., 1992; Lane, 1996). The base or 
foot of the receptor protrudes into the junctional membrane of the SR 
(where the dihydropyridine (DHP) receptors are located). The N-terminal is 
hydrophilic ("water loving") and protrudes into the sarcoplasm (see Figure 
2.5). The central channel is the calcium release channel essential for the 
contraction of skeletal muscle (Joffe et al., 1992; Lane, 1996). In MH the 
ryanodine receptor stays open, subsequently causing prolonged release of 
calcium into the muscle fibre (Galbraith et al., 1994). Why the receptor 
stays open is as yet unknown. 
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Figure 2.4. Top view of the ryanodine receptor as viewed by an electron 
microscope 
(Source: Joffe et al. , 1992) 
Cytosol 
SR 
membrane 
Interior 
/--<------
/ ;>-·--......,: 
--, 
Figure 2. 5. Schematic model of the ryanodine receptor 
(Source: Sorrentino & Volpe, 1993) 
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2.8 Signs & Symptoms 
When an MHS individual i~ expos6d to halothane or suxamethonium, a 
defect in the ryanodine receptor of the internal membrane of the muscle 
fibre (sarcoplasmic reticulum) causes the release of calcium into the 
skeletal muscle fibres, resulting in prolonged muscle contraction (Joffe et 
al., 1992). This continual contraction of the skeletal muscles leads to 
adenosine triphosphate (ATP) depletion. To overcome this, the body 
compensates by rephosphorylating ATP from adenosine diphosphate 
(ADP), thus resulting in excess heat production. Subsequently, aerobic 
and anaerobic metabolism are accelerated in the skeletal muscles leading 
to excess lactic acid levels (acidosis) (Joffe et al., 1992; Katz, 1992). 
Eventually cell membranes break down causing the release of·myoglobin, 
potassium and enzymes. If not treated, irreversible cell death c.an occur 
(Katz, 1992). 
Early symptoms of an MH attack involve: 
• An increase in heart rate and pulse rate (tachycardia). 
• Rapid, shallow respirations (tachypnoea). 
• Skeletal muscle rigidity. 
• Increase in blood pressure (hypertension). 
• Initially flushed skin, then pale (cyanotic) and unusually warm. 
• Abnormal brain wave pattern (dysrhythmia). 
• Increase in end-tidal carbon dioxide (ETC02) levels. 
The time scale of these events depends on the severity of the disease. 
(Merz, 1986; Katz, 1992; Maclennan, 1992) 
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As an attack progresses, impaired coagulation and subsequent bleeding 
from body orifices occurs, with pulmonary oedema, acidosis, high serum 
myoglobin levels, hyperthennia (over 44°C), and masseter muscle spasm 
(MMS) (Merz, 1986; Katz, 1992; Maclennan, 1992). 
Finally, if treatment is delayed or unavailable, there is an increase in blood 
potassium levels (hypeii<alaemia) and a decrease in blood pressure 
(hypotension), heart rate and pulse rate (bradycardia) with subsequent 
cardiac arrest (Merz, 1986; Katz, 1992). Death can occur within minutes 
from ventricular failure and within hours from pulmonary oedema or the 
inability to clot blood (coagulopathy). In the longer term, the disorder can 
be fatal days later from neurological damage or myoglobin in the urine 
(myoglobinurea), leading to renal failure (Maclennan, 1992; Ball & 
Johnson, 1S93). HO\Y8ver, with the development of end-tidal carbon 
dioxide (ETC~) analysers and other monitoring systems, an attack can be 
detected eartier, and dantrolene subsequently administered (see Section 
2.9 p. 19) (Maclennan, 1992; Lane, 1996). 
MH has been desaibed in species other than humans and is common in 
pigs (Maclennan, 1992). Porcine stress syndrome (PSS) is associated 
with lean heavily muscled breeds, notably Pietran and Lane/race. It was 
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noted that when these breeds were subjected to enormous stress, such as 
prior to slaughtering, they spontaneously died. Other causes of stress 
included overheating, exercise, mating and transportation. This is a major 
economic problem for the pork industry, as the meat produced is pale, soft 
and pliable (Maclennan, 1992; Loke & Maclennan, 1998). The symptoms 
of PSS are almost identical to that of human MH and include muscle 
rigidity, acidosis, increased body temperature, hyperkalaemia, and cardiac 
arrest (Britt, 1979; Jones & Round, 1990; Mccomas, 1996). However, 
unlike humans, stress is the main trigger of an MH crisis rn pigs. 
2.9 Treatment 
Dantrolene sodium (Dantrium, Pharmacia & Upjohn) is the most effective 
treatment for an MH attack if it is administered early intravenously (Merz, 
. 1986). Dantrolene is a muscle relaxant that reverses the effects of excess 
calcium in the skeletal muscle fibres by paralysing SR fundion and closing 
the calcium channels of the ryanodine receptor. Dantrolene does not 
interfere with nervous transmission to the muscle, nor with the 
depolarisation of the muscle membrane itself (Galbraith et al., 1994). 
Should an attack occur during surgery, the following procedures must be 
undertaken to ensure the safety of the patient: 
• Halt surgery. 
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• Discontinue triggering agents. 
• Administer intravenous (IV) dantrolene (within a 5-minute window 
period) - Dose: 1 mg/kg up to maximum of 1 Omg/kg over a 15--minute 
period. 
• Tum off vaporiser and change rubber tubing on anaesthesia machine. 
• Hyperventilate patient with 100% oxygen (02). 
• Reduce body temperature at several different sites: surface, 
intravenously, intragastrically, intrarectally, and at the site of surgical 
opening. If the body temperature is still high, then additional doses of 
dantrolene can be administered. 
• IV potassium chloride to reduce the effects of hyperkalaemia. 
• IV mannitol to reverse any cerebral or muscle oedema, and to help 
dislodge myoglobin from the nephrons. 
• If the surgery has to continue, then a trigger-free agent must be used, 
such as nitrous oxide and oxygen (N20:02), narcotics, tranquilisers, 
barbituates or non-depolarising muscle relaxants. 
(Merz, 1986; Lane, 1996) 
After the patient has been stabilised, a flare-up can occur on return to the 
recovery room or in the ward. Therefore, the patient has to be closely 
monitored for at least 24 hours in the intensive care unit (ICU) (Merz, 
1986). Patient monitoring involves the following: 
• Body temperature, especially axillary temperature 
• Electrocardiogram (ECG) 
I 
• End-tidal CO2 (ETC02) 
• Arterial oxygen saturation levels (pulse oximetry) 
• Blood pressure 
• Skin circulation and appearance 
• Blood gas analysis 
• Urine output 
• Serum electroJytes, especially potassium 
• Blood pH 
• Myoglobin levels 
And the administration of oral dantrolene - Dose: 4mg/kg per day. 
(Merz, 1986; Lane, 1996) 
2.10 Diagnosis 
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The most commonly used test to diagnose MH in humans, is the in-vitro 
. . ' 
contracture test (IVCT) or caffeine-halothane contracture test (CHCT). The 
. abbreviallon IVCT will be used from now on. Both caffeine and halothane 
have been shown to induce constant skeletal muscle contractions in 
muscle biopsies in the laboratory (Joffe et al., 1992; Abraham, Adnet, 
Glauber & Perel, 1998; Allen et al., 1998; Weppler et.al., 1998). There are 
two methods of the IVCT - deemed the North American method and the 
European method respectively. 
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The European method of diagnosing MH was standardised in 1983 
(European Malignant Hyperpyrexia Group, 1984). The protocol involves 
taking a biopsy from one of the muscles of the quadriceps group including 
a motor end point. The biopsy measures approximately 40mm long and 
30mm wide. The muscle is then placed in Kreb's-Ringer solution (see 
Appendix 1 Table A 1.1 p.62) v.here it is to be transported to the diagnostic 
laboratory. This solution mimics the extracellular ionic environment, 
nonetheless the muscle has to be tested within a 5 hour period or it will 
deteriorate beyond usefulness. When the muscle has been dissected into 
smaller strips (measuring 25mm x 3mm), it is placed into an organ bath at 
37°C and perfused with Kreb's-Ringer solution and equilibrated with 
carbogen (mixture of 95% oxygen and 5% carbon dioxide), and stimulated 
at a frequency of 0.2Hz. Three separate tests are performed. 
1 ) Static caffeine 
This invloves increasing the concentration of caffeine in the 
perfusate from 0.25 millimol per litre (mmol L-1) to 4.0 mmol L-1 
over a 3 minute period. 
2) Static haloth,me 
This involv<1s increasing the concentration of halothane in the 
perfusate from 0.5%v/v to 3.0%v/v over a 3 minute period. 
3) Dynamic halothane 
This involves stretching the muscle at a oonstant rate for 1 
minute, then increasing the halothane concentration from 
0.5%v/v to 3.0%v/v, until muscle tension is sustained at 0.2g-wt. 
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These three tests help to distinguish the MH status of the individual in the 
following three categories: 
1) Malignant hyperthennia susceptible (MHS) 
This is where the start of contracture (thresholrl) is less than or 
equal to 1.5mmol of caffeine, and is less than or equal to 
2.2%v/v of halothane. 
2) Malignant hyperthermia normal (MHN) 
This is where the start of contracture is greater than or equal to 
3mmol of caffeine without the contracture threshold . for 
halothane being greater than or equal to 3%v/v. 
3) Malignant hyperthermia equivocal (MHE) 
This is vmere only the caffeine threshold (MHEc) or the 
halothane threshold (MHEh) is reached, as per the MHS 
concentrations. However, these people are clinically regarded 
asMHS. 
(European Malignant Hyperpyrexia Group, 1984) 
The_North American method was standardised in 1987 (Larach, 1989) and 
is similar to the European method. The main biopsy sites are the 
quadriceps or the rectus abdominus, however a large mixed type 1/11 
muscle (such as biceps brachii) can also be used. The biopsies measure 
approximately 10-20mm long and 1-Smm wide. The organ bath and 
solutions are the same as the European method, however the testing 
protocols are different. 
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1 ) Halothane 
The concentration of halothane in the perfusate increases from 
2.7% to 3.3% over a period of 10 minutes. 
2) Caffeine 
The; concentration of caffeine in .. the perfusate increases from 
0.5 millimolar (mM) to 32mM over a period of 10 minutes. 
3) ,Joint caffeine-halothane 
This is an optional test performed by some laboratories and 
involves the muscle being exposed to 1 % halothane for 1 O 
minutes then increasing the concentration of caffeine from 
0.25mM to 32mM. 
The diagnosis for the North American method is also different as it does 
not use equivocals (MHE) as an MH status. A positive result can be one of 
the following: 
1) If the start of contracture (threshold) for halothane is greater 
than 0.2g-wt. 
2) lfthe start of contracture (threshold) for 2mM caffeine is greater 
than or equal to 0.2g~wt. 
3) If the start of contracture (threshold) occurs at a caffeine 
concentration of 1 mM or less in the presence of 1 % halothane. 
(Larach, 1989; Lane, 1996). 
The IVCT is a highly invasive technique as it involves the removal of a 
substantial mass of skeletal muscle from either a quadriceps or abdominal 
., .... __ ..... 
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muscle. This procedure is performed under a trigger-free general 
anaesthetic for children (and pigs), as it is less traumatic, and under a 
local anaesthetic for adults (Serfas et al., 1996). The testing procedure is 
also expensive. False-positive and false-negative results have been 
knovvn to occur, especially with the European method, as this protocol 
uses the MHE category. As the North American method only distinguishes 
people as either normal or susceptible, there is the less likelihood of 
producing false results (Maclennan, 1992). 
There is another form of the IVCT using the plant alkaloid, ryanodine. The 
_ryanodine contradure test (RCT) has been used by the European 
Malignant Hyperthermia Group since 1993 (Hopkins, Hartung, Wappler & 
EMHG, 1998). The biopsy (measuring 15-30mm x 2-3mm x 2-3mm) is 
removed from one muscle of the quadriceps group, usually the vastus 
lateralis. Like the IVCT the muscle is transported in Kreb's-Ringer, 
equilibrated with carbogen and testing performed within 5 hours. 
· Ryanodine (98-99% pure) is ·then added in 1 micromol (µmol) and 2µmol 
· •. concentrations, where three phases of contradure are observed. 
1 ) Start of COl".ltracture in minutes. ·· 
·_ 2) Time (minutes) when the contracture reaches 0.2g-wt. 
3) Time (minutes) YAlen the contracture reaches 1.0g-wt. 
· 11 has been found that MHS muscle contracts faster in these three phases 
· than MHN muscle. The RCT can also redyce the number of equivocals to 
either normal or susceptible, hence this· . test should. be . performed in 
·. : . ,' . . . 
t}\//;ifi;)>;,:_:·ii.f}t;iir\;;:j::;:r{::/\-':,//:r·:/ :·: --~!_,:,.· .:·:_.'.·~-::~.-- .. :i-.,:::. :,: ·::. 
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conjunction with the European IVCT (Weppler, Ro8\Y8r, Kochling, Scholz, 
Steinfath & Schulte-am·Esch, 1996; Hopkins et al., 1998). 
The main problem with the IVCT is that it cannot be used for screening the 
general population due to the low prevalence of the disease, the cost of 
performing the biopsies and the trauma of the procedure (Allen et al., 
1998). It is hoped in the future that a genetic test may be available for 
humans (Abraham et al., 1998), or a modified testing procedure requiring 
very small amounts of muscle that can be collected by needle biopsy. 
2.11 Genetics 
Malignant hyperthermia is commonly inherited as an autosomal dominant 
trait, but sporadic cases of autosomal recessiveness and codominance 
have been known to occur (Denborough, 1998). Six chromosome localities 
have been identified in human MH, the most common being expressed on 
·· chromosome 19. This chromosome contains the ryanodine receptor 1 
gene (RYR1 ) on its long arm (q), where linkage studies have found a 50% 
possibility that MH is connected to this gene (Lake, Tong, McCarthy & 
Maclennan, 1998). At present, 17 · point mutations have been located on 
the RYR1 gene (Lane, 1996; Wallace, Wooldridge, Kingston, Harrison, 
Ellis & Ford, 1996; Lake & Maclennan, 1998; Lake et al., 1998; Soto & 
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Sopher, 1998). Table 2.1 shows all the current chromosomal locations and 
the possible genes and mutations identified to these chromosomes. 
Table 2.1. Current chromosomal locations of human MH 
Chromosomal Gene 
Location 
1Sq13.1 RYR1 
17q11.2-q24 DHPR-gamma subunits 
(CACNLB1 & CACNLG) 
Sodium channel alpha-
subunit (SCN4A) 
7 q21.1 DHPR alpha 2/delta-
subunit (CACNL2A) 
3q13.1 Unidentified 
1 q32 DHPR alpha 1-subunit 
(CACNL1A3) 
5p.(short arm) Unidentified 
Mutation 
17 point mutations including: 
Arg615Cys; Gly2434Arg; 
Arg614Cys; Gly314Arg; 
Arg163Cys (wild type) 
Unidentified 
Gly1306Ala 
Unidentified 
Unidentifi • Kl 
Arg1086His 
Unidentified 
(Source: Censier, Urwyler, Zorzato & Treves, 1998; Denborough, 1998; Loke & 
Maclennan, 1998; Monsleurs, Van Broeckhoven, Martin, Van Hoof & Heytens, 1998) 
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In pigs, PSS is an autosomal recessive disease, and is associated with a 
single mutation in the RYR Arg615Cys gene on chromosome 6q (Joffe et 
al., 1992; Shomer, Mickelson & Louis, 1995; Lane, 1996; Laver, Owen, 
Junankar, Taske, Dulhunty & Lamb, 1997). The mutation in the RYR gene 
contains the amino acid substitution of cystine for arginine. This 
substitution is enough to alter the protein structure sufficiently to prevent 
the ryanodine receptor from closing properly (Mccomas, 1996). However, 
as this is a single point mutation, a genetic test is now available. The test 
requires 50µ1 of whole blood, and can be performed quickly and accurately 
(Maclennan, 1992). 
MH has also been linked to oth~r neuromuscular diseases (NMDs). There 
is a genetic link between MH and central core disease (CCD), as the gene 
for CCD is close to the RYR1 gene on chromosome 19q (Denborough, 
1998). CCD is an autosomal dominant disease and its clinical features 
include foot deformities, forward curving of the spine (kyphoscoliosis), 
congenital hip dislocation and joint con~ractures. Electron microscopic 
analysis revealed that the contractile apparatus in CCD muscle showed 
marked disintegration (Lake & Maclennan, 1998). 
· · MH may be related to two other NMDs, Duchenne muscular dystrophy 
(DMD) and King-Denborough syndrome (KOS) (Wedel, 1992). DMD is a 
sex-linked recessive disorder affecting young males, and the gene is 
located on chromosome Xp21. This disease causes progressive muscle 
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wasting due to the absence of the muscle protein dystrophin (Cummings, 
1994). Those DMD patients who have suffered an MH-type reaction during 
surgery usually test positive to the disease and account for approximately 
4% of all positive IVCTs (Lane, 1996). KOS affects males and its clinical 
features include a short, stocky stature, chest abnormalmes, 
kyphoscoliosis, a hump-back (thoracic kyphosis) and undescended testes 
(cryptorchidism). It has been found that those KOS patients who have had 
an MH crisis test positive to the disease (Lane, 1996). 
2.12 Prognosis 
The survival rate of MH in the 1990s is extremely high (96-97%). This is 
due to a better awareness of the disease and the consistent use of 
monitoring, by such means as blood gas analysis, body temperature and 
ETCO, analysis (Mertz, 1986; Lane, 1996). Familiarity with the MH 
protocols by surgical staff has led to the earlier cessation of trigger 
anaesthetics and the administration of IV dantrolene (Lane, 1996). 
HO\'\'ever, the IVCT still remains the only form of diagnosis for the disease 
in humans. The genetics involved in human MH are complicated 
compared to PSS, therefore a genetic test for humans is still a long way off 
(Joffe et al., 1992). 
. ··. • .. 
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CHAPTER3 
MATERIALS & METHODS 
3.1 Design 
The design used in this study consisted of the analysis of single skeletal 
muscle fibres using exogenous calcium and strontium ion activation, and 
the subsequent mathematical analysis of force-ion concenbation 
relationships. The method involved the chemical removal of the cell 
membrane from the single muscle fibre, thus leaving only the contractile 
apparatus. The SR was also disrupted, ensuring that all the internal 
calcium was removed to prevent any confounding of the results (Brill et al., 
1982; Fink et al. 1990). This method was used to examine the dynamics of 
the contractile and regulatory proteins in both MH and control muscle. It is 
also hoped that this study will indicate if another less invasive technique 
could be used to test for MH without compromising accuracy . 
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3.2 Muscle Biopsies 
Skeletal muscle biopsies (measuring 40mm x 30mm x 5mm) were 
removed from the vastus medialis muscle under a regional anaesthetic by 
RPH surgical staff. The MH status of the patient was unknown at this 
stage. The muscle biopsy was transported in Kreb's-Ringer solution to the 
Department of Neuropathology (Royal Perth Hospital) where it was divided 
into three portions: one portion for the IVCT (according to the European 
Malignant Hyperthermia Group protocol); one for histological analysis, and 
the last portion for this study. Only after the biopsy had undergone testing 
for this study was the result of the IVCT compared with the results 
obtained here. Biopsies determined as MHN ..w,re used as the controls for 
this present study. 
The biopsies used for the study were then transported in a relaxing 
solution containing 50% glycerol to prevent damage to the musde fibres 
(see Appendix 1 p.62). Musde testing was delayed for approximately 4 
days in order to remove any regional anaesthetic still remaining in the 
tissue. This did not impinge on the viability of the sample. 
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3.3 Ethical Considerations 
The study was approved by both the Edith Cowan University Ethics 
Committee and Royal Perth Hospital's Ethics Board. The muscle samples 
used were obtained after \Mitten consent from the patient (see Appendix 2 
p.64) on the day of admission. 
3.4 Equipment 
• microdissecting surgical instruments 
• dissecting binocular microscopes - Carl Ziess Jena Citoval 2, Leica 
Wild M3Z 
• fibre optic 1 OfN,/ cold light source 
• micro-force transducer and electrical amplifier/coupler 
• 3-D micromanipulator 
• multiple well, rotary solution holder 
• Deknatel, 10/0 black silk suture 
• Macintosh LC 575, Maclab 2E, Maclab GP Amp, Maclab v3.5 
ADlnstruments (see Figure 3.1) 
• Olympus digital camera 
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., Macintosh 
LC 575 
Figure 3. 1. Equipment setup for the skinned muscle fibre method 
3.5 Procedure 
Ten individual muscle fibres were removed from 8 biopsies. The individual 
muscle fibres were dissected from a muscle strip (measuring 10mm x 
2mm x 2mm). Ir., a petri dish, the muscle strip was covered by a layer of 
paraffin oil at 4°C in order to prevent the muscle from drying out. 
Microdissecting instruments and a dissecting microscope illuminated by a 
fibre optic cold light source were used to dissect free the individual muscle 
fibres. Each fibre was tied with 10/0 black silk suture at each end, forming 
a loop with the diameter of a 19 gauge needle ( see Figure 3.2). The fibre 
was then mounted onto the stainless steel forceps and pin of the 
transducer (see Figures 3.3 & 3.4), where it was adjusted to optimal length 
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for contraction by trial and error, and measured length by width (divisions) 
using a graticule (8 divisions equated to 1 mm). 
The fibre was dipped in 2% Triton X-100 (detergent) in relaxing solution I 
(Appendix 1 Table A1.2 p.62) for 10 minutes to render the membrane 
permeable, and then into the weaker relaxing solution Ill (Appendix 1 
Table A1 .3 p.62) for a further 60 seconds, where the force signal was set 
to electrical zero. The fibre was subsequently tested at various 
concentrations of calcium and strontium, from the weakest through to the 
strongest concentration (Appendix 1 Tables A1.4 & A1.5 p.63). This is the 
gradual or "stepping" increase in concentration to see where the muscle 
begins to contract. When the fibre contracted it pulled against the pin of 
the transducer. This altered the electrical resistance of the transducer, 
causing a voltage change at the input stage of the GP Amp. The signal 
was digitised by the Maclab computer system and displayed on the 
computer screen as a continuous graph of force versus time. Force 
maxima and minima were logged against ionic concentration for 
subsequent analysis by fitting a mathematical equation to the data (Fink et 
al., 1990). Experiments were performed at room temperature (22-24°C). 
Fibre 
Muscle striQ 
I G I 
2mm 
Figure 3.2. Individual muscle fibre (top) tied with silk sutures 
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Figure 3.3. Individual muscle fibre mounted on stainless steel 
forceps (left) and pin of the transducer (right) 
Carousel 
Figure 3.4. Location of the stainless forceps and transducer (and pin) in a multiple well solution holder (carousel) 
38 
39 
3.6 . Data Analysis 
The datum points logged on Maclab v3.5 (Macintosh AD Instruments 
scientific software) \N8re converted to Microsoft Excel format, 'Atlich was 
then reinterpreted in DeltaPoint Delta Graph Pro 3.5 to produce plots of 
the calcium concentration (pCa)- and strontium concentration (pSr)-force 
relationships ( see below). Curve parameters ( affecting slope and lateral 
shift - see Hill Equation p. 40) between MH equivocal (MHE) and normal 
(control) data were analysed by paired Student t-test. Differences \Y8re 
considered statistically significant if P<0.1. Values were represented as 
mean ± standard error of the mean (S.E.M). Measured fibre width was 
used to calculate force per cross-sectional area (F/CSA - see p. 41). The 
data were categorised into two groups: controls and MHE. 
pCa- pSr-force Relationships: 
• pCaso and pSrro equates to 50% of the maximum activated for 
response. This value indicates the relative sensitivity of the contractile 
apparatus to each activating ion. 
• pCa10 and pSr10 equates to 10% of the maximum activated force 
response. This value indicates the activation threshold of the 
contractile apparatus to each activating ion. 
• pCaro-pSrro is the difference in relative sensitivity of the contractile 
apparatus to the two activating ions . 
. (Stephenson, O'Callaghan & Stephenson, 1994) 
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Hill Equation: 
The Hill coefficients (nea and nsr) reflect the steepness of the curve (fitted 
from the datum points) by the following equation: 
where: Pr = relative force 
K = constant ( as defined below) 
x2• = concentration of Ca2• or sr2• 
Ho\Y8ver the above equation was altered in order to calculate these 
solutions. The calculation is as follows: 
Parameters set by Fink et al., 1990 for normal human skeletal muscle 
(Type I and II) are defined in the following table: . 
. Table 3.1 Parameters of normal human skeletal muscle 
nca 
n5r 
pCSsJ 
pCa10 
pSrso 
pSr10 
pCaso,.pSrro 
(Fink et al., 1990) 
Typel 
2.20 (±0.06) 
2.30 (±0.1) 
6.05 (±0.05) 
6.48 (±0.06) 
5.61 (±0.09) 
6.10 (±0.07) 
0.32 (±0.04) 
Type II 
4.70 (±0.3) 
4.30 (±0.3) 
6.07 (±0.02) 
. 6.27 (±0.01) 
4.76 (±0.04) 
4.99 (±0.02) 
1.31 (±0.04) 
The values in the brackets represent the standard error of the mean 
(± S.E.M.). This is expressed as the following: 
SEM = un-1 /~n 
(Fink et al. 1 1990; Stephenson et at., 1994; Lynch, Hayes, Lam, & 
·. Williams, 1993; Lynch, Stephenson & Williams, 1995) 
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Force per cross-sectional area (F/CSA): 
This equates to the maximum activated force of Ca2• and sr2+ divided by 
the cross-sectional area of the fibre. The calculations are as follows: 
CSA= nr2 
where: 1t = Pi 
r = radius 
Force= ma 
. where: m = mass (g) 
a= acceleration constant (9.8m/sec2) 
Force was expressed in milliNewtons per millimetres (mN/mm2) for this 
study. 
Parameters set by Fink et al., 1990 (in N/cm2) for normal human skeletal 
muscle (Type I and II) are as follovvs: 
Type I 
Type II 
26.1 (±2.7) 
30.1 (±9.0) 
Brackets represent± S.E.M. 
(Fink et al., 1990) 
.· 3.7 Limitations. 
. . . 
· ·· · The study was limited to the biopsy samples supplied by Royal Perth 
Hospital. 
This had several implications for the study, namely: 
• There was no control over the number of MHN, MHS or MHE samples. 
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• Biopsies from only one muscle (Vastus medialis) were available. 
• · As muscle biopsies are only removed from patients undergoing elective 
surgery, there was a risk of the surgery being postponed or cancelled, 
thus affecting the collection of samples. 
• There was no control over the quality and amount of muscle in the 
received biopsy samples. 
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CHAPTER4 
4.1 Results 
As a consequence of routine MH testing at the Department of 
Neuropathology, Royal Perth Hospital, 8 biopsy samples \N8re made 
available for use in this study. Of those, 6 'N8re deemed by the IVCT to be 
normal (controls), whilst the remaining 2 were categorised as equivocal 
(MHE). Ten individual muscle fibre segments (approximately 0.~1mm in 
length) were dissected from each biopsy, resulting in a total of SO fibres 
. (60 control, 20 MHE) being studied. Of the 80 fibres only 72 fibres (57 
control, 15 MHE) were analysed, as the remaining 8 fibres (3 control, 5 
MHE) v.,ere unresponsive. This may have been due to fibre damage during 
dissection and mounting in the apparatus, or during the original biopsy 
removal. 
. Normal (Control) Fibres 
Of the 57 fibres collated, only 45 could be classified as either Type I (slow-
twitchl fihres or Type II (fast-twitch) fibres according to the parameters 
defined by Fink et al. (1990) (see Section 3.6 p.40). Fifteen fibres were 
classified as Type I (Table 4.1 ). vvhere the slope values showed that the 
force-pCa (nca) and force-pSr (ns,) curves were relatively shallow (nca, nsr 
<2) (Figure 4.1 ). The fibres showed a greater than . normal sensitivity 
(pCas, - pSra, = 0.92) compared to the results reported by Fink et al. 
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(1990) with a value of 0.32 (Table 3.1 p.40). The force per cross-sectional 
area (F/CSA) generated by strontium (Sr•) was four times greater than 
that of calcium (Ca2•). The other thirty fibres were classified as Type II 
fibres (Table 4.1 ). The force-pea and force-pSr curves were relatively 
. steep (>2) (Figure 4.3) and sensitivity to calcium and strontium was less 
than that of the Type I fibres with a value of --0.62. The F/CSA was greater 
in sr• than it was for ca2•. 
The other 12 fibres could not be categorised as either fast-·or slow-twitch 
fibres, as these fibres displayed unusual or mixed characteristics. Although 
the mean slope values displayed in Table 4.1 are charaderistic of fast 
twitch fibres, many individual fibres displayed shallow nea curves (slope 
values from 1 to 2) and very steep nsr curves ( slope values as either 1 or 
3) (Figure 4.5). The reverse occasionally occurred where the ca2• curves 
were steeper than the sr2• curves. These fibres also showed an average 
· sensitivity of 1.29 (pCasi - pSrro), and the F/CSA for sr2• was three times 
. greater than that of ca2•. 
MHEFibres 
Of the 15 fibres analysed only 5 could be categorized as being either fast 
or slow twitch, of which four fibres were classified as Type I (Table 4.1). 
The force-pea ( <1.40; statistical significance P<0.1) and force-pSr curves 
(ns, <2.13) were relatively shallow (Figure 4.2), and· the fibres were 
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generally less sensitive than the controls giving a value of pCaso - pSrm = 
. -3.01. The·. F/CSA was far greater in the sr2• series (63.61mN/mm2; 
statistical significance P<0.1) than in the ca2• series (15.13mN/mm2) but 
overall less than the controls. Only one fibre could be categorised as a 
fast-twitch fibre (Table 4.1 ), however the nca and ns, curves were steeper 
(2.13 and 3.37 respectively) (Figure 4.4). The sensitivity of this fibre was 
less than that of the control fibres, giving a value of -1.06 (pCas:, - pSrm). 
The F/CSA generated was more in ca2• than sr2• (24.87mN/mm2 and 
16.51 mN/mm2 respectively) but overall less than the control fibres. 
There were 10 fibres of mixed characteristics (Table 4.1) where the force-
pCa curves were generally shallow (nea<2; statistical significance P<0.1) 
and the force-pSr cuNes were generally very steep (n&>2.5) (Figure 4.6). 
These fibres were less sensitive to ca2• and sr• (pCBs> - pSrro = 1.52) 
than that of the control mixed fibres, and the F/CSA by sr2+ (68.97 
·mN/mm2) was greater than that of the Ca2+ (43.06 mN/mm2) .. 
Comparisons 
For Type I fibres (see Figures 4.1 & 4.2), the values of nca, pCas:,, pCa10 
and F /CSA (both Ca2• and Sr+) for control fibres were greater than for the 
equivocals. The equivocal fibres YJere more sensitve than the controls for 
nSr, pSrm and pSr10. However, the equivocals responded better to the sr2• 
solution than the Ca2•1 but the controls were overall more sensitive to the 
two act!vating ions (Table 4.1 ). Statistically, there 'M:lre significant 
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differences for nea. ns, and F/CSA for sr2• (P<0.1) between the controls 
and the MHE fibres. 
For Type II fibres (see Figures 4.3 & 4.4), the values of nca, F/CSA (Ca2• 
and Sr2+) and sensitivity (pCas,.pSrro) for control fibres were greater than 
for the_ equivocals. The equivocals Y1ere greater than the controls for slope 
(ns,), activation threshold (pCa10 and pSr10) and relative sensitivity (pCasc, 
and pSrro) to each activating ion (Table 4.1). This group could not be 
statistically analysed due to only one MHE fibre being found. 
For the mixed fibre group (see Figures 4.5 & 4.6), the controls were more 
sensitive ·10 nca, pCa10 and F/CSA csr2·). The ;equivocals were more 
.·· sensitive to nSr, pCa10. and relative sensitivity to each activating ion (pCaa, 
· and pSr50). Overall, the MHE fibres were more sensitive {pCaro-pSroo) than 
the controls (Table 4.1 ). Statistically, there were significant differenc:es for 
nea, nar and pCa,o (P<0.1 ). 
Table 4. 1. Contractile parameters of control and MHE-skeletal muscle fibre types 
Type I 
Control MHE 
samples (n) 15 
nca. 1.75 ±0.09 
pCaao 7.43 ±1.25 
pCa10 8.00 ±1.26 
F/CSA 50.83 ±10.85 
ns, 1.82 ±0.12 
pSrso 6.52 ±0.58 
pSr10 7.08 ±0.56 
F/CSA 200.53 ±52.41 
pCa1cr·pSrso 0.92 ±1.24 
Data are represented as mean ±S.E.M. 
*Denotes statlstlcal significance at P<0.1 
4 
1.40 ±0.19* 
4.90 ±0.61 
5.63 ±0.70 
15.13 ±3.30 
2.13 ±0.11* 
7.90±0.94 
8.35±0.92 
63.61 ±22.44* 
-3.01 ±1.33 
Type II 
Control MHE 
30 1 
2.82 ±0.97 - 2.13 
5.10 ±0.19 5.49 
5.45 ±0.19 5.93 
79.20 ±14.94 24.87 
2.78 ±0.10 3.37 
5.73 ±0.38 6.55 
6.08 ±0.39 6.83 
173.31 ±33.97 16.51 
-0.62 ±0.43 -1.06 
Mixed: 
Control MHE 
12 10 
2.57 ±0.28 1.57 ±0.13* 
5.20 ±0.28 5.74 ±0.33 
5.61 ±0.29 6.38 ±0.35* 
41.65 ±12.33 43.06 ±10.30 
2.14 ±0.25 3.16 ±0.40* 
3.90 ±0.24 4.22 ±0.42 
4.42 ±0.26 4.55 ±0.43 
127.86 ±44.75 68.97 ±35.41 
1.29 ±0.43 1.52 ±0.59 
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4.2 Discussion 
The aim of this study was to compare the djfferences between normal 
(control) human skeletal muscle and MH positive (MHS) skeletal muscle. 
As no actual MHS muscle was available, only muscle classified as MH 
equivocal (MHE) was used. 
The skinned muscle fibre technic;'_ e (used in this study) identifies the 
contractile kinetics of single skeletal muscle fibres to exogenous calcium 
and strontium ion activation. Differences in the kinetics of responses to 
Ca2+ can indicate functional differences of the contractile proteins (myosin 
S1 subfragment)1 whereas differences in the kinetics of responses to sr2+ 
can indicate functional differences of the regulatory proteins (troponin and 
tropomyosin) (Stephenson et al., 1994). 
The MHE Type I fibres displayed greater sensitivity to sr2+ (pSrro 7.90) 
vmich suggests that there are functional differences in the regulatory 
proteins, whereas the MHE mixed fibres were more sensitive to Ca2+ 
(pCaro 5.74) which is indicative of a greater reactivity in the contractile 
proteins as well. The MHE Type II fibre showed no significant differences 
in sensitivity to either ion as it was almost identical in slope and lateral shift 
to the Type II control fibres. 
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The most noticeable differences between the MHE muscle and the control 
muscle, were observed during the testing phase on the Maclab system. 
Most of the MHE fihres were more sensitive to the weaker Ca2+ and sr2+ 
solutions resulting in stronger contractions, Ykiereas the normal muscle 
was unresponsive. However, these effects on the MacLab could not be 
reproduced in Delta Graph as the calculation of the Relative Force 
normalised these values. 
The F/CSA generated by the control fibres was generally greater than that 
of the equivocals for both Ca2+ and sr2+. As fibre diameter is usually 
greater in MHS muscle than that of normal muscle (Lane, 1996), equivocal 
muscle has not been measured in any published studies, therefore F/CSA 
is unknown in these cases. However, there was a negative statistical 
significance (F/CSA P<0.1) between the Type I fibres for MHE and 
controls during sr2+ adivation. 
The skinned muscle fibre technique (involving Ca2+ and sr2+) has been 
used extensively in the research of Duchenne Muscular Dystrophy (DMD) 
in both humans and rodents. In comparison to the human DMD contractile 
parameters performed by Fink et al. (1990), both the controls and MHE 
fibres (fast and slow fibres) were more sensitive to sr2+ than to Ca2+. In 
comparison to normal mammal skeletal muscle (Wilson & Stephenson, 
1990), again both the controls and MHE fibres were more sensitive to sr2+, 
notably pSrm and pSr10. Normal rat soleus muscle however VAS slightly 
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different (Stephenson et al., 1994). The controls and MHE fibres were 
more sensitive to pCas:, and pSrw (fast and slow fibres) than just one type 
of ion. On the whole, the slope parameters (nca and nsr) for all these 
examples (human DMD, mammal and rat) were unique to each case, and 
rarely did the controls and MHE fibres (from this study) have similar 
values. 
The caffeine skinned muscle fibre technique conducted by Britt et al. 
(1982), involved only the chemical disruption of the sarcolemma. In this 
study, they were testing the ca2• release from the SR on exposure to 
caffeine. They found that this technique provided more information about 
the calcium release mechanism of the intact SR than that of the IVCT. 
Takagi, Sunohara & Nonaka (1980) found in a similar study that the 
caffeine contracture threshold was lower in MHS muscle fibres than for 
normal muscle fibres. 
Fibre type composition in human MH is rarely tested, however a study 
compiled by Heiman-Patterson, Fletcher, Rosenberg & Tahmoush ( 1987) 
found that fibre type profiles and MH did not correlate. The same also 
applied in fibre studies conduded in porcine stress syndrome (PSS). 
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4.3 Conclusion 
The contractile and regulatory proteins are all interconnected with non-
contractile proteins to fonn a complex cytoskeleton that holds and 
stabilises the muscle fibre during relaxation and contraction (Sugita, 1997). 
The non-contractile protein dystrophin binds to the actin filament 
(regulatory protein). Dystrophin also binds to the inner and outer 
membrane, therefore playing an important role in the stabilisation of the 
muscle cell (Sugita, 1997). In response to the first hypothesis: Individual 
MH muscle fibres display differing kinetics of contraction to exogenous 
calcium and strontium ion activation than individual muscle fibres in normal 
(control) human muscle, both the contractile and regulatory proteins 
appeared to be affected by this disease. Therefore, this would impact on 
the mechanics of the Mole muscle fibre, such as making it unstable 
during contraction. However, to determine if these two proteins are 
affected, positive MH muscle needs to be examined to draw a definite 
conclusion. For the second hypothesis: The force per cross-sectional area 
generated by MH muscle fibres is different to that of normal (control) 
muscle, the FICSA generated by the MHE muscle fibres was less than that 
of the control muscle. However the Type I and mixed fibres did display 
greater FICSA to sr2+ rather than to Ca2+, as did the control fibres in all 
three fibre types. 
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The main problem with this study was the availability of muscle samples. 
The majority of the biopsies 'N8re performed for other reasons than a 
family history of MH. For example, biopsies were performed for unusual 
reactions to a previously administered general anaesthetic such as raised 
blood carbon dioxide levels. Erring on the side of caution, the hospital had 
to investigate all unusual reactions if further elective surgery was required. 
Other problems encountered were the cancellation of surgery six times in 
the period of muscle testing and the status of every individual not being 
knovvn on the day of admission. Therefore obtaining positive MH biopsies 
was unpredictable. Also, accessibility to the genetic information of the 
individual (if they were from an MH family) was unobtainable for this study. 
4.4 Further developments 
Although this study provided limited results, the skinned fibre method 
using caffeine has been previously applied to this disease and has shown 
some promising results. If this method could be refined (using exO'i;ienous 
cti-•, sr2•, caffeine and possibly ryanodine on intact as well as skinned 
fibres), then the technique could be used as a replacement to the IVCT. If 
so, the benefits to the patient (in terms of muscle biopsies) and the 
community at large could be a positive step forward. 
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APPENDIX 1 
Tables 
Table A 1. 1 Kreb's~Ringer Solution 
NaCl 
l<CI 
MgS04 
KH2P04 
Glucose 
NaHC03 
CaCl2H20 
pH 
118.1 mmol L-1 
3.4 mmol L-1 
0.8 mmol L-1 
1.2 mmol L-1 
11.1 mmol L-1 
25.0 mmol L-1 
2.5 mmol L-1 
7.4 
(European Malignant Hyperpyrexia Group, 1984) 
Table A 1.2 Relaxing Solution I 
HEPESa 60mM 
MgCl2 1mM 
EGTAb 50mM 
NaAzide 1mM 
Caffeine 1 OmM 
ATPc BmM 
pH 7.1 
Relaxing Solution I & 50% Glycerol: 
Same solution components as Table A 1.2 made up to 1 OOmls1 plus 
1 OOmls of glycerol. 
Table A 1.3 Relaxing Solution Ill 
HEPES8 
MgCl2 
HDTAd 
NaAzide 
Caffeine 
ATP0 
pH 
60mM 
1mM 
50mM 
1mM 
10mM 
BmM 
7.1 
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Table A1.4 Calcium Solution 
HEPES' 
CaCO:, 
M9Cl2 
EGTA• 
NaAzide 
Caffeine 
ATP' 
pH 
60mM 
48.5mM 
1mM 
50mM 
1mM 
10mM 
8mM 
7.1 
NB. Solutions of varying concentration were made by mixing the above with Relaxing 
Solution I 
Table A1.5 Strontium Solution 
HEPES' 
SrCO:, 
MgCl2 
EGTA• 
NaAzide 
Caffeine 
ATP' 
pH 
60mM 
40mM 
1mM 
50mM 
1mM 
10mM 
8mM 
7.1 
NB. Solutions of varying concentration were made by mixing the above with Relaxing 
Solution I 
Legend: 
• HEPES: N-(2-hydroxyethyl] piperazine-N'-[2-ethanesulfonic acid] 
• EGTA: ethyleneglycol-bis(J3-aminoethylelher)-N,N,N',N',-tetraacetate 
' ATP: adenosine 5-triphosphate 
• HDTA: hexamethylenediamine-N, N, N' ,N' -tetraacetate 
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APPEND1X2 
Patient Consent Form 
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s11r.vro11 PAil): c .. Mrt'$ 
~ s,1t, s.m:1 Royal Perth Hospital wnr.,~r.TOHSf],[J:;;-J' CA>IP!!S w,11:,.110, S1ttr1 t,11k. w,. W.O SHf.hTOl'I P>.U IOOf 
W6.n'U1' ,1,,U$~L!>. 
~, ~o, X:l I) ClfO 
n:ll'li tin 
~t:<;''"" !l:'fl 9ll:l 71~ I 
r ... ;,,;1c: (oil 9Jll 11!1 
DEPARTMENT OF 1'iEUROPA11IOLOGY 'J,"f~l L~ll t.lJ!:'1 JV ti~ 
PATIENT CONSENT FORM 
':'cfrf""-""'~ tr:O ~ll' nu 
r,e.1~.~ (CIJ ?~• HLI 
T.T,Y.UK (Cf) ti,• >l,1t 
TEL~ (61-8) 9224 2433 
FAX: (61-8) 9224 255'6 
CONSENT FOR THE use OF BIOPSY TISSUE FOR DISEASE RESEARCH 
of ....................................................................................................................... . 
hereby give permission for a section cf th:s muscle biopsy to be used in 
disease research. 
I understand that only !issue not required for the '.esting procedures for which 
the bicpsy was taken will be used for rcse.:lrch purposes. 
I realise that this permission can be withdrawn at any time. 
The purpose of thls consent form has been explained to me. 
Signature: ........................................................ . 
Dated: ...................................... . 
Witness daclaration 
1, ....................................................................................................................... . 
have read over and explained to the consenting party the- purpose cf this 
consent and they affixed lheir signature in my presence. 
Witness signature .................................................. . On ............................ . 
